News

Filter

1 to 9 of 19 results

Funding restrictions for rituximab and eltrombopag widened in New Zealand

Funding restrictions for rituximab and eltrombopag widened in New Zealand

20-02-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of proposals to widen…

Asia-PacificeltrombopagFinancialGlaxoSmithKlineHealthcareImmunologicalsNew ZealandPharmaceuticalrituximabRoche

AbbVie to spend $320 million to establish Singapore manufacturing presence

AbbVie to spend $320 million to establish Singapore manufacturing presence

06-02-2014

US drugmaker AbbVie says it plans to invest $320 million to establish operations in Singapore for small…

AbbVieAsia-PacificImmunologicalsOncologyPharmaceuticalProduction

CSL Behring’s Hizentra approved in Japan for PID and SID

CSL Behring’s Hizentra approved in Japan for PID and SID

27-09-2013

The Japanese Ministry of Health, Labor and Welfare has approved Hizentra for the treatment of primary…

Asia-PacificCSL BehringHizentraImmunologicalsPharmaceuticalRare diseasesRegulation

Additional indications in Japan for Roche's Avastin and Astellas' Prograf

17-06-2013

Swiss drug major Roche (ROG: SIX) says that the Japanese Ministry of Health, Labor and Welfare (MHLW)…

Asia-PacificAstellas PharmaAvastinBiotechnologyImmunologicalsOncologyPharmaceuticalPrografRegulationRoche

Hikma in-licenses inhaled insulin for MENA; Advaxis and FusionVax Asia deal

23-04-2013

Jordan-based Hikma Pharmaceuticals (LSE: HIK) has signed a licensing and distribution agreement with…

AdvaxisADXS-HPVAsia-PacificDance 01Dance BiopharmDiabetesFusionVaxHikma PharmaceuticalsImmunologicalsLicensingOncologyPharmaceuticalRest of the World

Osiris gets second approval for Prochymal, in New Zealand

15-06-2012

USA-based Osiris Therapeutics (Nasdaq: OSIR) has received a second approval to market its first-in-class…

Asia-PacificBiotechnologyImmunologicalsOsiris TherapeuticsProchymalRegulation

1 to 9 of 19 results

COMPANY SPOTLIGHT

Menarini

Back to top